Children and youths who are prescribed antipsychotic medications have multiple, potentially fatal, dose-related cardiovascular, metabolic, and other adverse events, but whether or not these medications are associated with an increased risk of death is unknown.
T he introduction of second-generation antipsychotics led to a marked increase in antipsychotic medication prescribing for children and youths. [1] [2] [3] In 2010, more than 1.3 million individuals receiving antipsychotics aged 24 years or younger filled 7 million antipsychotic medication prescriptions. 4, 5 The most common diagnoses associated with the antipsychotic prescriptions for these children and young adults were attention-deficit/hyperactivity disorder (ADHD), disruptive behavior disorder, and depression. 4, 5 However, antipsychotics are often an off-label or secondary therapeutic choice for these diagnoses, given the other well-defined therapeutic interventions available with potentially fewer adverse effects. 5 Antipsychotics also are frequently prescribed to children and adolescents for bipolar disorder or mood instability, although there often are alternative treatments available. 5 Studies of older adults linking antipsychotics with increased risk of cardiovascular 6, 7 and total mortality 8 raise the concern that receipt of antipsychotics may be associated with increased mortality in younger populations. Antipsychotics have potentially life-threatening cardiovascular, 6, 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] metabolic, [20] [21] [22] [23] [24] and other [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] adverse effects, although in children and adolescents, these adverse effects are most frequently associated with medication overdose and fatal outcomes are rare. However, there is little information from controlled studies of the association of antipsychotics with mortality in younger populations. Thus, we conducted a retrospective cohort study examining unexpected deaths among children and youths beginning therapy with antipsychotics or alternative medications.
Methods

Cohort and Follow-up
The cohort was identified from Tennessee Medicaid enrollment, pharmacy, hospital, outpatient, and nursing home files, which were augmented with linkage to death certificates 40, 41 and data from a statewide hospital discharge database. 42 These resources provided an efficient source of data for identifying the cohort, determining periods of probable exposure to medications, and ascertaining deaths. 40, 43 The study was reviewed and approved by the institutional review boards of Vanderbilt University, Nashville, Tennessee, and the State of Tennessee Health Department, which waived informed consent.
Medications
Medication use was identified from Medicaid pharmacy files, which are not subject to information bias 43 and have high concordance with patient self-reports of medication use. [44] [45] [46] Study medications were oral antipsychotics (eTable 1 in the Supplement) and 3 classes of control drugs commonly prescribed for the same indications as antipsychotics (eTable 2 in the Supplement). Control medications included (1) psychostimulants, serotonin-norepinephrine reuptake inhibitors, or α-agonists frequently prescribed for ADHD or other problems of behavior or conduct; (2) antidepressants, such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and mirtazapine, which are commonly recommended as initial therapy for major depression and other mood disorders 47 ; and (3) lithium or anticonvulsant mood stabilizers, absent evidence of a neurologic indication.
Cohort Eligibility
The cohort included children and young adults (youths) aged 5 to 24 years enrolled in Medicaid between January 1, 1999, and December 31, 2014. The lower age limit coincides with initiation of school attendance for many children with the consequent social and behavioral demands. The upper age limit coincides with the World Health Organization's definition of youth, 20 corresponds closely to the age of emerging adulthood (defined as ages 18 to 25 years), 48 and is consistent with other studies of psychoactive drugs in younger populations. 3, 20, 49, 50 Sensitivity analyses were performed with an upper age bound of 21 years, which is consistent with the US Food and Drug Administration definition of adolescents, 51 and with a lower age bound of 12 years. Cohort members (eTable 3 in the Supplement) had at least 1 year of Medicaid enrollment and previous health care use to ensure availability of data for study variables. We excluded patients with life-threatening somatic illnesses (eTable 4 in the Supplement) or who were in the hospital when the medication regimen was started, for whom illness-related deaths might be indistinguishable from those associated with adverse medication events. Individuals were not included if they had a diagnosis of schizophrenia or related psychoses (antipsychotics are the only pharmacotherapy) or a neurologic indication for an antipsychotic. A psychiatric diagnosis in the past year was required to exclude patients with nonpsychiatric indications for study medications.
Antipsychotic Medication and Control Groups
The cohort included new users (no filled prescription in the past year) of antipsychotic and control medications to capture deaths early in therapy and to ensure that baseline covariates were unaffected by long-term medication effects. 52 Patients who received antipsychotics could have previous use of up to 2 control medication classes. Control patients could have no previous use of antipsychotics but could have use of
Key Points
Question Are antipsychotic medications prescribed for children and youths without psychosis associated with increased risk of unexpected death or deaths other than from injuries or suicides without prolonged hospitalization?
Findings In this cohort study of 247 858 Medicaid-enrolled children and youths in Tennessee who were new users of antipsychotic or control medications, the group that received a higher dose of antipsychotic medication had a significantly increased risk of unexpected death compared with the group that received control medication.
Meaning This study suggests that antipsychotic treatment may be associated with increased mortality among children and youths and appears to underscore recommendations for careful medication use and monitoring in this population. the 2 other control medication classes. Thus, on cohort entry, patients in each group could have up to 3 study medication classes (multiple medications within each class were permitted). Sensitivity analyses excluded patients with more severe comorbidities, such as bipolar disorder, autism or Asperger syndrome, or intellectual disability, and patients prescribed a baseline mood stabilizer.
Follow-up
Patients entered the cohort at the filling of the first prescription for an antipsychotic or control drug that satisfied the cohort eligibility criteria. They left the cohort at the earliest of the following times: (1) the end of the study period, (2) 5 years after cohort entry (1 year in a sensitivity analysis), (3) loss of Medicaid enrollment, (4) reached age of 25 years, or (5) death.
Follow-up for controls ended with an antipsychotic prescription; for those receiving antipsychotics, follow-up ended with use of all 3 control drug classes. Follow-up also ended after 365 days (30 days in sensitivity analysis) with no filled prescription for the cohort entry drug class. 6, 7, 20 Both patients who received antipsychotics and control patients who left the cohort could reenter if they subsequently met the study eligibility criteria. Because these episodes were not overlapping and the end point occurred only once, statistical independence assumptions were satisfied.
53
Because many adverse effects of antipsychotic medications are acute and therapy may be episodic, study persontime was restricted to periods of current medication use, which were calculated from the prescriptions for study drugs filled between cohort entry and exit (eMethods 1 and eFigure in the Supplement). Current use began with the prescription fill and ended with the earliest of the end of the dispensed days of supply (with 1 additional day given for the long half-life of many study medications), filling of a subsequent prescription for a drug in the same class (which initiated a new period of current use), or the end of study follow-up. For patients admitted to the hospital on a day of current study medication use, study person-time extended up to 7 days to capture in-hospital deaths associated with preadmission conditions. Antipsychotic use was stratified according to timedependent dose, 6 given the wide dose range for which antipsychotics are prescribed 20 and the strong dose-response for the cardiovascular, 6,7 metabolic, 20 and central nervous system-depressant 54,55 effects of antipsychotics. The dose cutpoint was more than 50 mg of chlorpromazine or its equivalent (eTable 3 in the Supplement), the approximate median antipsychotic dose on cohort entry.
End Points
Study deaths were those that occurred out of the hospital or within 7 days after hospital admission. In younger populations free of life-threatening somatic illness, out-of-hospital deaths often reflect disease processes with rapid onset, which would include unexpected adverse events associated with the medication. In the study population, nearly all qualifying inhospital deaths were attributable to ultimately fatal acute preadmission conditions (eg, severe head injury or drowning). A sensitivity analysis further restricted study deaths to those within 1 day of hospital admission. Deaths due to injury or suicide had an underlying cause of death of unintentional injury other than a drug overdose or suicide. All other deaths were unexpected deaths, which absent adverse medication events, are rare among children and youths in good or stable health (eMethods 2 and eTables 5-7 in the Supplement). This definition is consistent with a National Institutes of Health and Centers for Disease Control and Prevention research initiative to reduce mortality in younger populations 56 except that it includes deaths due to unintentional overdose, because for both children and adults, antipsychotics are potent central nervous system depressants 54, 55 that can impair respiration [25] [26] [27] [28] [29] [30] and thus possibly could be synergistically associated with an increase in risk of overdose of other drugs. Unexpected deaths not due to overdose were identified and classified as deaths due to cardiovascular or metabolic causes or other deaths. Deaths due to overdose were described according to specific medications listed as multiple causes of death in the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (eTable 8 in the Supplement).
Statistical Analysis
Statistical analysis was performed from January 1, 2017, to August 15, 2018. To control for potential differences in psychiatric and somatic comorbidity, we measured 46 covariates plausibly associated with both antipsychotics and mortality (eMethods 3 and eTable 9 in the Supplement). These factors included demographic characteristics; psychoactive medications; psychiatric, neurologic, and cardiovascular conditions; respiratory diseases; injuries, other illnesses and psychiatric and somatic hospitalizations; and other medical care use. The analysis controlled for covariates with stabilized inverse probability of treatment weights calculated from the propensity score 57-59 defined as the probability that a cohort member was an antipsychotic user given covariates (eMethods 4 and eTables 9 and 10 in the Supplement). If the propensity score is properly constituted, the weighting eliminates covariate imbalances between the study groups and thus controls for confounding by variables included in the propensity score (eMethods 4 in the Supplement).
57-59
Because the factors leading to lower-vs higher-dose antipsychotic use could differ, we calculated a time-dependent propensity score 53 for each group. Antipsychotic dose, age, calendar year, and psychoactive medications were timedependent because changes during follow-up may be associated with the risk of death. Other covariates were fixed at cohort entry given that they could be on the causal pathway for antipsychotic-associated deaths (eg, obesity or type 2 diabetes).
The adjusted relative risk of death was estimated with a weighted proportional hazards regression with weights truncated at the 99th percentile 60 (eMethods 4 in the Supplement). A 2-sided P < .05 was considered to be statistically significant. All statistical analyses were performed with SAS, version 9.4 (SAS Institute Inc). (Table 1) . These differences were more pronounced in the higher-dose group. The prevalence of diagnosed or treated cardiovascular illness was low and differed little between the study groups. After adjustment for the propensity score, the distribution of study covariates was comparable in all 3 groups (eTable 9 in the Supplement).
Results
Cohort
Deaths
Cohort follow-up included 123 005 person-years in the control group, 16 159 person-years in the lower-dose group, and 27 354 person-years in the higher-dose groups. There were 67 deaths in the control group (54.5 per 100 000 person-years; 95% CI, 42.9-69.2 per 100 000 person-years) (Figure) , with injuries and suicides accounting for 67.2% of deaths. There were 8 deaths in the lower-dose group (49.5 per 100 000 personyears; 95% CI, 24.8-99.0 per 100 000 person-years), which did not differ significantly from the incidence in the control group (P = .80). There were 40 deaths in the higher-dose group (146.2 per 100 000 person-years; 95% CI, 107.3-199.4 per 100 000 person-years), which was significantly greater than the incidence in the control group (P < .001). The difference was primarily attributable to the increased incidence of unexpected deaths (higher-dose group vs control group, 76.8 per 100 000 person-years vs 17.9 per 100 000 person-years), which accounted for 52.5% of deaths in the higher-dose group.
After adjustment for covariates, the risk of death in the higher-dose group was 80% greater than that in the control group (hazard ratio [HR], 1.80; 95% CI, 1.06-3.07) ( Table 2 ). In the higher-dose group, the adjusted HR for unexpected deaths was significantly increased (HR, 3.51; 95% CI, 1.54-7.96), with 45 excess deaths per 100 000 person-years (range, 10-125 per 100 000 person-years). In contrast, the risk of death from injury or suicide was not increased (HR, 1.03; 95% CI, 0.53-2.01). Patients in the lower-dose group had no significantly increased risk of total mortality (HR, 1.43; 95% CI, 0.62-3.30;
When more detailed causes of death were examined (Table 2), the higher-dose group had an increased risk of unexpected deaths other than from unintentional drug overdose (HR, 3.50; 95% CI, 1.35-9.11), including increased risk for deaths due to cardiovascular or metabolic causes (HR, 4.29; 95% CI, 1.33-13.89). There was an increased risk of deaths due to unintentional drug overdose, but the difference was not significant (HR, 3.51; 95% CI, 0.99-12.43; P = .052). Deaths due to overdose in the control group were predominantly associated with opioids and illegal drugs, whereas those deaths in the higher-dose group more often involved nonopioid prescription medications (eTable 12 in the Supplement). There was no significantly increased risk of death from either injury (HR, 1.21; 95% CI, 0.54-2.73) or suicide (HR, 0.74; 95% CI, 0.26-2.15).
Sensitivity Analyses
The increased risk for unexpected death in the higher-dose group persisted in sensitivity analyses that restricted the study cohort ( Table 3) . These analyses changed the upper age limit to 21 years and the lower age limit to 12 years and excluded patients with bipolar disorder, previous mood stabilizer use, autism or Asperger syndrome, or intellectual disability.
The increased risk also persisted when key study definitions were altered (Table 3 ). These study definitions included time-dependent covariates for psychiatric and somatic hospitalizations, not allowing cohort reentry, considering patient as a random effect in the statistical analysis, censoring patients after 30 days without a prescription fill for the study medication class, restricting in-hospital deaths to within 1 day of admission, and not truncating the inverse probability of treatment weights.
A sensitivity analysis assessed the association of an unmeasured confounder (eTable 13 in the Supplement). To explain the risk of unexpected death in the higher-dose group, the confounder would have to increase risk by 5-fold, have a 75% prevalence in the higher-dose antipsychotic treatment group, and not be present in control patients.
Discussion
Among study children and youths without life-threatening somatic illness or psychosis who initiated antipsychotic therapy, those receiving doses higher than 50-mg chlorpromazine equivalents during follow-up had an 80% increased risk of death that was attributable to a 3.5-fold increased risk of [25] [26] [27] [28] [29] [30] and thus could increase risk of fatal inadvertent overdose with other medications. Our analysis that did not consider overdoses as unexpected deaths showed increased risk of comparable magnitude to that of the primary analysis. For every 100 000 person-years of follow-up, the higherdose group had 45 excess unexpected deaths, which exceeded the 44 deaths per 100 000 person-years from unintentional injuries other than overdoses in this group, a major focus of public health campaigns for children and youths. 63, 64 If the association observed were causal, improving the safety of antipsychotic medication prescribing for the more than 1 million young persons who receive antipsychotics annually in the United States 4 would be of high priority.
The study findings seem to reinforce existing guidelines for improving the outcomes of antipsychotic therapy in children and youths. 5, 65 These guidelines include restriction to indications for which there is good evidence of efficacy, adequate trial of alternatives including psychosocial interventions when possible, cardiometabolic assessment before treatment and monitoring after treatment, and limiting therapy to the lowest dose and shortest duration possible. 
Limitations
The primary limitation of this study is the potential for uncontrolled confounding by differences between antipsychotic users and controls. Because the number of deaths during follow-up was relatively small, the analysis relied on statistical adjustment for an extensive set of covariates to control for the substantially greater psychiatric comorbidities among antipsychotic users. Furthermore, study data (1) did not include important patient characteristics, such as body mass index, family history, or undiagnosed cardiovascular abnormalities; (2) were subject to underdiagnosis of risk factors; and (3) lacked information necessary to refine the end point definitions through psychological autopsies. Several findings indicated that the study results were not attributable to confounding. The propensity score-based weighting balanced the distribution of measured comorbidities among the study groups. There was no increase in the adjusted risk for suicides, which should reflect unmeasured differences in serious psychiatric comorbidity. Sensitivity analyses that decreased comorbidity differences by restricting the cohort had essentially similar findings. Further studies are needed that compare antipsychotic users and controls within more narrow comorbidity ranges or in analyses that include richer clinical data.
The significantly elevated risk of death due to cardiovascular or metabolic disease is important because this end point should be less subject to unmeasured confounding and the finding is consistent with known antipsychotic adverse effects in children and youths. The prevalence of cardiovascular conditions was low and did not differ among the study groups. In younger populations, the corrected QT interval increases during antipsychotic treatment, 9 and there are at least 10 published case reports of antipsychotic-related, acquired long QT syndrome, including torsade de pointes. 
Conclusions
Children and youths beginning antipsychotic therapy who received doses higher than 50-mg chlorpromazine equivalents had a 3.5-fold increased risk of unexpected deaths but no increased risk for deaths from injuries or suicides. This finding suggests that the increased unexpected death risk was associated with the use of antipsychotics. These results appear to reinforce recommendations for careful prescribing and monitoring of antipsychotic regimens for children and youths and the need for larger antipsychotic safety studies in this population. This supplement provides additional details for the study of antipsychotics and risk of unexpected death in children and youth and should be read in conjunction with the primary manuscript (MS).
Sources of Data
All study data were obtained from Tennessee Medicaid files, an efficient data source for identifying the cohort, determining periods of probable exposure to medications, and ascertaining deaths.
1,2 The study Medicaid database included enrollment, pharmacy, hospital, outpatient, and nursing home files and was augmented with linkage to death certificates 1, 3 and a statewide hospital discharge database. The linkages used all available identifiers.
Study Medications
Antipsychotics, control drugs and other medications were identified from Medicaid pharmacy files. These included the date the prescription was dispensed, drug, quantity, dose, and days of supply. Computerized pharmacy records are an excellent source of medication data because they are not subject to information bias 2 and have high concordance with patient self-reports of medication use. [4] [5] [6] The residual misclassification should be limited and, if non-differential, should bias towards the null. 1 The study included oral antipsychotics available in Tennessee Medicaid during the study period (eTable 1). The control drugs (eTable 2) are alternative treatments for the indications for which antipsychotics are prescribed, including psychostimulants and other medications for attention deficit hyperactivity disorder (ADHD) and other disruptive behaviors, antidepressants commonly used as initial treatment for mood disorders and mood stabilizers. eTable 1 shows the equivalent doses for study antipsychotics. 5  Perphenazine c  10  Chlorpromazine HCL  100  Pimozide  2  Chlorprothixene  50  Quetiapine  75  Fluphenazine HCL  2  Risperidone  2  Haloperidol  2  Thioridazine  100  Iloperidone  6  Thiothixene  5  Loxapine succinate  15  Trifluoperazine HCL  5  Lurasidone  20  Triflupromazine HCL  25  Mesoridazine besylate  50  Ziprasidone  60  Molindone  10 a The use of clozapine or any depot antipsychotic was considered to indicate psychosis and thus was an exclusion criterion. Promazine was not included as a study antipsychotic because 99% of the small number of encounters were for administration of the short-acting injectable formulation. b Includes fluoxetine-olanzapine combination. c Includes perphenazine-amitriptyline combination.
The cohort included new episodes of therapy for the study medications during the period 1/1/1999 through 12/31/2014. Identification of cohort patients began with the filling of the first prescription (fill date t0) during the study period that qualified the patient as a new user of either an antipsychotic or one of the three classes of a control medication (the cohort entry class).
New users of antipsychotics had no prior antipsychotic prescription filled in the interval [t0 -364, t0-1] a . However, they could have had past prescriptions for up to two classes of control medications. The concurrent use of control medications with antipsychotics was tracked as a study covariate ( §6).
New users of a control medication class could have no prior prescription for a medication in the cohort entry class filled in the interval [t0 -364, t0-1]. Furthermore, they could not have a filled antipsychotic prescription in that interval. However, they could have past use of other control drug classes. Thus, patients in each group could have use of up to three study medication classes.
New users of anticonvulsant mood stabilizers had to meet further criteria to assure that the medication was initiated for a psychiatric indication. The primary issues were: 1) study anticonvulsant mood stabilizers such as the valproates also are frequently prescribed for seizure disorders and other neurologic indications and 2) some anticonvulsants that were not study drugs are occasionally prescribed as mood stabilizers. In order to exclude neurologic patients, we required that patients have no diagnosis indicating a potential neurologic indication in the past year, including seizure disorder/convulsions, migraine, other neuropathic pain or that they have a diagnosis of a bipolar or related disorder in the past year and no diagnosis of a seizure disorder/convulsions in the past 30 days. Furthermore, we did not permit prior prescription (regardless of indication) of either study anticonvulsant mood stabilizers or other anticonvulsants that occasionally are prescribed as mood stabilizers (gabapentin, pregabalin, lacosamide, levetiracetam, tiagabine, topiramate, zonisamide).
eTable 2. Control Medications
The notation denotes a 364 day interval that begins 364 days before t0 and ends on the day prior to t0. 
Study Person-time
Because many antipsychotic adverse effects are acute, the person-time included in the study analysis was restricted to periods of current drug use. These periods were calculated from the prescriptions for drugs in the cohort entry class filled between cohort entry and exit, as described below.
Cohort Entry and Exit
Patients entered the cohort on the date of the first prescription that qualified them as a new user of a study medication. The cohort exit date was the first of the following dates:
1. End of the study; 2. A period of 364 days with no filling of a study drug prescription in the cohort entry class that led to cohort entry. If ti was the fill date of the most recent prescription for a medication in the cohort entry class, then the exit date was ti+364 if there had not been a refill. On ti+365 the patient would be eligible to reenter the cohort as a new user. 3. Day prior to the 25th birthday; 4. Day prior to failure to meet the TennCare enrollment criteria ( eTable 3, criterion 2); 5. The date of death; 6. For control medication patients, the day prior to the filling of an antipsychotic prescription. 7. For antipsychotic patients, the day prior to overlapping use of three control medication classes ( eTable 3, criterion 8).
Patients who failed to meet the eligibility criteria related to medical history or illnesses ( eTable 3, criteria 3-7) during followup did not exit the cohort. The motivation was to avoid censoring related to a drug-related deterioration in health. Because this could introduce bias if one group of patients had a less favorable prognostic trajectory, a sensitivity analysis restricted study followup to one year, during which time such changes should be minimal. Results were similar to those from the primary analysis (MS Table 3 ).
Patients who left the cohort could reenter if they subsequently met the study eligibility criteria. For example, a control patient who started an antipsychotic would enter the cohort as an antipsychotic patient if they qualified for the cohort on the fill date. Since the episodes were non-overlapping and the end point occurred only once, statistical independence assumptions were satisfied. 11 
Study Person-Time
For each cohort member, the prescriptions filled for drugs in the cohort entry class between cohort entry and exit defined study person-time ( eFigure 1). Study person-time for each individual prescription was restricted to the period of probable current drug use for that prescription. If there was a gap between prescriptions, indicating periods off drug (e.g., eFigure 1, interval between prescriptions 1 and 2), that persontime was not included in the analysis.
For an individual prescription (i), current use began on the date of the prescription fill (ti-1) and extended through the end of the days of supply+1. The additional exposure day allowed for the long half-life of the study drugs. Study person-time for that prescription could include the entire period of current use. However, study person-time could terminate sooner if, prior to the end of current use: 1) a subsequent prescription for a drug in the cohort entry class was filled (defining the beginning of person-time for that prescription); or 2) the patient exited the cohort. For patients admitted to the hospital (not considering single-day hospitalizations) during a period of current medication use, up to the first 7 days of hospitalization was included in study person-time to capture deaths following a short hospitalization, even if the period of current use had ended.
eFigure. Study Person-time
Antipsychotic study person-time was stratified according to time-dependent antipsychotic dose, given the strong dose-response for the cardiovascular, 12,13 metabolic, 14 and CNS-depressant 15, 16 effects of antipsychotics. The dose cutpoint was >50 mg of chlorpromazine or its equivalent ( eTable 1), the median antipsychotic dose on cohort entry.
A single person could have person-time for both the higher and lower dose categories in the analysis. Because these time periods were non-overlapping and the endpoint (death) occurred only once, statistical independence assumptions were not violated. 
Enters cohort Exits cohort
Study person-time for each prescription restricted to the period of current use: the prescription fill date ( ) through the end of the days of supply ( ) plus one
Study drug prescriptions
Depicts a single patient who has n filled study drug prescriptions between cohort entry and exit. Control medications as covariates. Cohort patients could use control medications not in the cohort entry class. Examples include either a new antipsychotic or bipolar medication user with ADHD medication use. Because the control medication class leading to cohort entry could convey important prognostic information (e.g., ADHD vs bipolar medication), the psychoactive medication covariates included the control medications.
Time-dependent covariates. The values of study covariates were either defined at cohort entry and held fixed throughout followup or were allowed to vary during followup (time-dependent), with the values updated at the time of each prescription fill during followup ( eFigure 1). 11 The time-dependent covariates were those thought to be acutely related to mortality and not on the causal pathway for drug-related deaths. Thus, the time-dependent covariates included age and calendar year (given the long study followup period), control medications, and other psychoactive medications (e.g., benzodiazepines, opioids). No other covariates were time-dependent because these could be on the causal pathway between medication use and death. Examples include obesity or diabetes (potentially medication-related adverse effects) and psychiatric hospitalization (possible suboptimal initial medication choice).
A sensitivity analyses that limited the potential for covariate changes by restricting followup to one year from cohort entry had essentially similar findings to those of the primary analysis (MS Table 3 The psychoactive medication covariates reflected recent use because the acute effects of these drugs could affect mortality (e.g., cyclic antidepressants, benzodiazepines, opioids). The ascertainment for control drugs ended on t0-1 because use on t0 could indicate study drug assignment and thus be a surrogate for treatment group. The diagnosis ascertainment extended to t0+1 because some of the diagnostic workup related to the initiation of drug therapy could occur on the day following the first prescription (see §3 above).
For time-dependent covariates, the ascertainment interval was relative to ti ( eFigure 1).
b The notation denotes a period beginning 90 days prior to t0 and ending on the day prior to t0. Table shows the hazard ratio that would result after adjustment for an unmeasured confounder, using the method originally described by Breslow and Day. 29, 30 Confounding would completely explain an increased risk of unexpected death only for a confounder that increased the risk of unexpected death by a factor of 5, was present for at least 75% of higher-dose antipsychotic users, and was not present in any of the controls
